<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="decrease">
            <roleset id="decrease.01" name="make smaller&#x0A;" wordnet="2">
                <roles>
                    <role n="0" descr="agent&#x0A;" />
                    <role n="1" descr="thing decreased&#x0A;" />
                    <role n="2" descr="location&#x0A;" />
                </roles>
                <example src="PERMUTATE" no="0">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and Disruption of narL has significantly decreased nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="1">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and Disruption of narL is observed to have significantly decreased nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="2">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and Disruption of narL significantly decreased nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="3">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and Disruption of narL was observed to have significantly decreased nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="4">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and Treatment with melatonin has significantly decreased lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="5">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and Treatment with melatonin is observed to have significantly decreased lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="6">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and Treatment with melatonin significantly decreased lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="7">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and Treatment with melatonin was observed to have significantly decreased lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="8">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and lipid peroxide synthesis have been significantly decreased by Treatment with melatonin will significantly.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="9">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and lipid peroxide synthesis were significantly decreased by Treatment with melatonin will significantly.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="10">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and nitrite induction of the nirB promoter have been significantly decreased by Disruption of narL will significantly.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="11">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and nitrite induction of the nirB promoter were significantly decreased by Disruption of narL will significantly.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="12">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Disruption of narL can have significantly decreased nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="13">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Disruption of narL can significantly decrease nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="14">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Disruption of narL could significantly decrease nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="15">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Disruption of narL is able to significantly decrease nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="16">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Disruption of narL is believed to have significantly decreased nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="17">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Disruption of narL is believed to significantly decrease nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="18">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Disruption of narL is observed to significantly decrease nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="19">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Disruption of narL is shown to have significantly decreased nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="20">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Disruption of narL is shown to significantly decrease nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="21">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Disruption of narL may have significantly decreased nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="22">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Disruption of narL may significantly decrease nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="23">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Disruption of narL might significantly decrease nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="24">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Disruption of narL significantly decreases nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="25">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Disruption of narL was able to significantly decrease nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="26">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Disruption of narL was believed to significantly decrease nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="27">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Disruption of narL was shown to significantly decrease nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="28">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Disruption of narL will significantly decrease nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="29">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Disruption of narL would significantly decrease nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="30">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Treatment with melatonin can have significantly decreased lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="31">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Treatment with melatonin can significantly decrease lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="32">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Treatment with melatonin could significantly decrease lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="33">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Treatment with melatonin is able to significantly decrease lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="34">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Treatment with melatonin is believed to have significantly decreased lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="35">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Treatment with melatonin is believed to significantly decrease lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="36">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Treatment with melatonin is observed to significantly decrease lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="37">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Treatment with melatonin is shown to have significantly decreased lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="38">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Treatment with melatonin is shown to significantly decrease lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="39">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Treatment with melatonin may have significantly decreased lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="40">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Treatment with melatonin may significantly decrease lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="41">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Treatment with melatonin might significantly decrease lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="42">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Treatment with melatonin significantly decreases lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="43">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Treatment with melatonin was able to significantly decrease lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="44">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Treatment with melatonin was believed to significantly decrease lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="45">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Treatment with melatonin was shown to significantly decrease lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="46">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Treatment with melatonin will significantly decrease lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="47">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Treatment with melatonin would significantly decrease lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="48">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and lipid peroxide synthesis are significantly decreased by Treatment with melatonin will significantly.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="49">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and lipid peroxide synthesis can be significantly decreased by Treatment with melatonin will significantly.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="50">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and lipid peroxide synthesis can have been significantly decreased by Treatment with melatonin will significantly.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="51">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and lipid peroxide synthesis could be significantly decreased by Treatment with melatonin will significantly.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="52">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and lipid peroxide synthesis is able to be significantly decreased by Treatment with melatonin will significantly.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="53">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and lipid peroxide synthesis is believed to be significantly decreased by Treatment with melatonin will significantly.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="54">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and lipid peroxide synthesis is shown to be significantly decreased by Treatment with melatonin will significantly.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="55">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and lipid peroxide synthesis may be significantly decreased by Treatment with melatonin will significantly.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="56">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and lipid peroxide synthesis may have been significantly decreased by Treatment with melatonin will significantly.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="57">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and lipid peroxide synthesis might be significantly decreased by Treatment with melatonin will significantly.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="58">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and lipid peroxide synthesis was able to be significantly decreased by Treatment with melatonin will significantly.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="59">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and lipid peroxide synthesis was believed to be significantly decreased by Treatment with melatonin will significantly.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="60">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and lipid peroxide synthesis was shown to be significantly decreased by Treatment with melatonin will significantly.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="61">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and lipid peroxide synthesis will be significantly decreased by Treatment with melatonin will significantly.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="62">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and lipid peroxide synthesis will have been significantly decreased by Treatment with melatonin will significantly.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="63">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and lipid peroxide synthesis would be significantly decreased by Treatment with melatonin will significantly.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="64">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and nitrite induction of the nirB promoter are significantly decreased by Disruption of narL will significantly.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="65">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and nitrite induction of the nirB promoter can be significantly decreased by Disruption of narL will significantly.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="66">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and nitrite induction of the nirB promoter can have been significantly decreased by Disruption of narL will significantly.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="67">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and nitrite induction of the nirB promoter could be significantly decreased by Disruption of narL will significantly.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="68">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and nitrite induction of the nirB promoter is able to be significantly decreased by Disruption of narL will significantly.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="69">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and nitrite induction of the nirB promoter is believed to be significantly decreased by Disruption of narL will significantly.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="70">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and nitrite induction of the nirB promoter is shown to be significantly decreased by Disruption of narL will significantly.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="71">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and nitrite induction of the nirB promoter may be significantly decreased by Disruption of narL will significantly.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="72">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and nitrite induction of the nirB promoter may have been significantly decreased by Disruption of narL will significantly.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="73">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and nitrite induction of the nirB promoter might be significantly decreased by Disruption of narL will significantly.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="74">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and nitrite induction of the nirB promoter was able to be significantly decreased by Disruption of narL will significantly.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="75">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and nitrite induction of the nirB promoter was believed to be significantly decreased by Disruption of narL will significantly.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="76">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and nitrite induction of the nirB promoter was shown to be significantly decreased by Disruption of narL will significantly.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="77">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and nitrite induction of the nirB promoter will be significantly decreased by Disruption of narL will significantly.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="78">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and nitrite induction of the nirB promoter will have been significantly decreased by Disruption of narL will significantly.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="79">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and nitrite induction of the nirB promoter would be significantly decreased by Disruption of narL will significantly.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="80">
                    <text>Deletion of the arcA gene has caused about a 2-fold increase in the ptsG expression, and Disruption of narL will have significantly decreased nitrite induction of the nirB promoter.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="81">
                    <text>Deletion of the arcA gene has caused about a 2-fold increase in the ptsG expression, and Treatment with melatonin will have significantly decreased lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="82">
                    <text>Disruption of narL can decrease nitrite induction of the nirB promoter, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="83">
                    <text>Disruption of narL could decrease nitrite induction of the nirB promoter, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="84">
                    <text>Disruption of narL decreased nitrite induction of the nirB promoter, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="85">
                    <text>Disruption of narL decreases nitrite induction of the nirB promoter, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="86">
                    <text>Disruption of narL has decreased nitrite induction of the nirB promoter, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="87">
                    <text>Disruption of narL is able to decrease nitrite induction of the nirB promoter, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="88">
                    <text>Disruption of narL is believed to decrease nitrite induction of the nirB promoter, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="89">
                    <text>Disruption of narL is shown to decrease nitrite induction of the nirB promoter, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="90">
                    <text>Disruption of narL may decrease nitrite induction of the nirB promoter, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="91">
                    <text>Disruption of narL might decrease nitrite induction of the nirB promoter, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="92">
                    <text>Disruption of narL was able to decrease nitrite induction of the nirB promoter, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="93">
                    <text>Disruption of narL was believed to decrease nitrite induction of the nirB promoter, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="94">
                    <text>Disruption of narL will decrease nitrite induction of the nirB promoter, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="95">
                    <text>Disruption of narL would decrease nitrite induction of the nirB promoter, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="96">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, methionine content was significantly decreased (4050%; see Table 2).</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="PERMUTATE" no="97">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels can be lowered and the RELN mRNA content can be decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the RELN mRNA content</arg>
                </example>
                <example src="PERMUTATE" no="98">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels can have been lowered and the RELN mRNA content can have been decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the RELN mRNA content</arg>
                </example>
                <example src="PERMUTATE" no="99">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels is able to be lowered and the RELN mRNA content is able to be decreased), and neither RAP2 nor RAP3 is be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the RELN mRNA content</arg>
                </example>
                <example src="PERMUTATE" no="100">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels is lowered and the RELN mRNA content is decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the RELN mRNA content</arg>
                </example>
                <example src="PERMUTATE" no="101">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels may be lowered and the RELN mRNA content may be decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the RELN mRNA content</arg>
                </example>
                <example src="PERMUTATE" no="102">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels may have been lowered and the RELN mRNA content may have been decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the RELN mRNA content</arg>
                </example>
                <example src="PERMUTATE" no="103">
                    <text>In contrast, only low levels of the truncated RAP1 peptides have been detected (consistent with that expression levels has been lowered and the RELN mRNA content has been decreased), and neither RAP2 nor RAP3 has been co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the RELN mRNA content</arg>
                </example>
                <example src="PERMUTATE" no="104">
                    <text>In contrast, only low levels of the truncated RAP1 peptides were detected (consistent with that expression levels could be lowered and the RELN mRNA content could be decreased), and neither RAP2 nor RAP3 was co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the RELN mRNA content</arg>
                </example>
                <example src="PERMUTATE" no="105">
                    <text>In contrast, only low levels of the truncated RAP1 peptides were detected (consistent with that expression levels might be lowered and the RELN mRNA content might be decreased), and neither RAP2 nor RAP3 was co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the RELN mRNA content</arg>
                </example>
                <example src="PERMUTATE" no="106">
                    <text>In contrast, only low levels of the truncated RAP1 peptides were detected (consistent with that expression levels was able to be lowered and the RELN mRNA content was able to be decreased), and neither RAP2 nor RAP3 was be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the RELN mRNA content</arg>
                </example>
                <example src="PERMUTATE" no="107">
                    <text>In contrast, only low levels of the truncated RAP1 peptides were detected (consistent with that expression levels was lowered and the RELN mRNA content was decreased), and neither RAP2 nor RAP3 was co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the RELN mRNA content</arg>
                </example>
                <example src="PERMUTATE" no="108">
                    <text>In contrast, only low levels of the truncated RAP1 peptides will be detected (consistent with that expression levels will be lowered and the RELN mRNA content will be decreased), and neither RAP2 nor RAP3 will be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the RELN mRNA content</arg>
                </example>
                <example src="PERMUTATE" no="109">
                    <text>In contrast, only low levels of the truncated RAP1 peptides will be detected (consistent with that expression levels will have been lowered and the RELN mRNA content will have been decreased), and neither RAP2 nor RAP3 will be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the RELN mRNA content</arg>
                </example>
                <example src="PERMUTATE" no="110">
                    <text>In contrast, only low levels of the truncated RAP1 peptides would be detected (consistent with that expression levels would be lowered and the RELN mRNA content would be decreased), and neither RAP2 nor RAP3 would be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the RELN mRNA content</arg>
                </example>
                <example src="PERMUTATE" no="111">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and expression of OmpF porin can be decreased by marA locus in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="112">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and expression of OmpF porin could be decreased by marA locus in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="113">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and expression of OmpF porin has been decreased by marA locus in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="114">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and expression of OmpF porin is able to be decreased by marA locus in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="115">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and expression of OmpF porin is believed to be decreased by marA locus in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="116">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and expression of OmpF porin is decreased by marA locus in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="117">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and expression of OmpF porin may be decreased by marA locus in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="118">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and expression of OmpF porin might be decreased by marA locus in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="119">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and expression of OmpF porin was able to be decreased by marA locus in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="120">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and expression of OmpF porin was believed to be decreased by marA locus in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="121">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and expression of OmpF porin was decreased by marA locus in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="122">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and expression of OmpF porin will be decreased by marA locus in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="123">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and expression of OmpF porin would be decreased by marA locus in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="124">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and marA locus can decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="125">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and marA locus could decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="126">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and marA locus decreased expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="127">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and marA locus decreases expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="128">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and marA locus had the ability to decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="129">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and marA locus has the ability to decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="130">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and marA locus is able to decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="131">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and marA locus is believed to decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="132">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and marA locus may decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="133">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and marA locus might decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="134">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and marA locus was able to decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="135">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and marA locus was believed to decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="136">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and marA locus will decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="137">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and marA locus would decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="138">
                    <text>Treatment with melatonin can decrease lipid peroxide synthesis whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="139">
                    <text>Treatment with melatonin can have decreased lipid peroxide synthesis whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="140">
                    <text>Treatment with melatonin could decrease lipid peroxide synthesis whilst not suppressing induction by nitrate, suggesting that there could be a second nitrate-responsive factor.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="141">
                    <text>Treatment with melatonin decreased lipid peroxide synthesis whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="142">
                    <text>Treatment with melatonin decreases lipid peroxide synthesis whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="143">
                    <text>Treatment with melatonin has decreased lipid peroxide synthesis whilst not suppressing induction by nitrate, suggesting that there might be a second nitrate-responsive factor.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="144">
                    <text>Treatment with melatonin has the ability to decrease lipid peroxide synthesis whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="145">
                    <text>Treatment with melatonin is able to decrease lipid peroxide synthesis whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="146">
                    <text>Treatment with melatonin is believed to decrease lipid peroxide synthesis whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="147">
                    <text>Treatment with melatonin is shown to decrease lipid peroxide synthesis whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="148">
                    <text>Treatment with melatonin may decrease lipid peroxide synthesis whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="149">
                    <text>Treatment with melatonin may have decreased lipid peroxide synthesis whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="150">
                    <text>Treatment with melatonin might decrease lipid peroxide synthesis whilst not suppressing induction by nitrate, suggesting that there might be a second nitrate-responsive factor.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="151">
                    <text>Treatment with melatonin was able to decrease lipid peroxide synthesis whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="152">
                    <text>Treatment with melatonin was believed to decrease lipid peroxide synthesis whilst not suppressing induction by nitrate, suggesting that there might be a second nitrate-responsive factor.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="153">
                    <text>Treatment with melatonin was shown to decrease lipid peroxide synthesis whilst not suppressing induction by nitrate, suggesting that there might be a second nitrate-responsive factor.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="154">
                    <text>Treatment with melatonin will decrease lipid peroxide synthesis whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="155">
                    <text>Treatment with melatonin will have decreased lipid peroxide synthesis whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="156">
                    <text>Treatment with melatonin would decrease lipid peroxide synthesis whilst not suppressing induction by nitrate, suggesting that there might be a second nitrate-responsive factor.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="157">
                    <text>levels of Clara cell have been reported in several cardiac promoters and marA locus was shown to decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="158">
                    <text>overexpression of ArcA can decrease glucose consumption whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="159">
                    <text>overexpression of ArcA can decrease glucose consumption, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="160">
                    <text>overexpression of ArcA can have decreased glucose consumption whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="161">
                    <text>overexpression of ArcA could decrease glucose consumption whilst not suppressing induction by nitrate, suggesting that there could be a second nitrate-responsive factor.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="162">
                    <text>overexpression of ArcA could decrease glucose consumption, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="163">
                    <text>overexpression of ArcA decreased glucose consumption whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="164">
                    <text>overexpression of ArcA decreased glucose consumption, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="165">
                    <text>overexpression of ArcA decreases glucose consumption whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="166">
                    <text>overexpression of ArcA decreases glucose consumption, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="167">
                    <text>overexpression of ArcA has decreased glucose consumption whilst not suppressing induction by nitrate, suggesting that there might be a second nitrate-responsive factor.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="168">
                    <text>overexpression of ArcA has decreased glucose consumption, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="169">
                    <text>overexpression of ArcA has the ability to decrease glucose consumption whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="170">
                    <text>overexpression of ArcA is able to decrease glucose consumption whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="171">
                    <text>overexpression of ArcA is able to decrease glucose consumption, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="172">
                    <text>overexpression of ArcA is believed to decrease glucose consumption whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="173">
                    <text>overexpression of ArcA is believed to decrease glucose consumption, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="174">
                    <text>overexpression of ArcA is shown to decrease glucose consumption whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="175">
                    <text>overexpression of ArcA is shown to decrease glucose consumption, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="176">
                    <text>overexpression of ArcA may decrease glucose consumption whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="177">
                    <text>overexpression of ArcA may decrease glucose consumption, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="178">
                    <text>overexpression of ArcA may have decreased glucose consumption whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="179">
                    <text>overexpression of ArcA might decrease glucose consumption whilst not suppressing induction by nitrate, suggesting that there might be a second nitrate-responsive factor.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="180">
                    <text>overexpression of ArcA might decrease glucose consumption, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="181">
                    <text>overexpression of ArcA was able to decrease glucose consumption whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="182">
                    <text>overexpression of ArcA was able to decrease glucose consumption, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="183">
                    <text>overexpression of ArcA was believed to decrease glucose consumption whilst not suppressing induction by nitrate, suggesting that there might be a second nitrate-responsive factor.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="184">
                    <text>overexpression of ArcA was believed to decrease glucose consumption, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="185">
                    <text>overexpression of ArcA was shown to decrease glucose consumption whilst not suppressing induction by nitrate, suggesting that there might be a second nitrate-responsive factor.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="186">
                    <text>overexpression of ArcA will decrease glucose consumption whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="187">
                    <text>overexpression of ArcA will decrease glucose consumption, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="188">
                    <text>overexpression of ArcA will have decreased glucose consumption whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="189">
                    <text>overexpression of ArcA would decrease glucose consumption whilst not suppressing induction by nitrate, suggesting that there might be a second nitrate-responsive factor.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="190">
                    <text>overexpression of ArcA would decrease glucose consumption, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="191">
                    <text>promoter activity in cardiomyocytes can be decreased by their mutation.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="192">
                    <text>promoter activity in cardiomyocytes can have been decreased by their mutation.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="193">
                    <text>promoter activity in cardiomyocytes could be decreased by their mutation.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="194">
                    <text>promoter activity in cardiomyocytes has been decreased by their mutation.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="195">
                    <text>promoter activity in cardiomyocytes is able to be decreased by their mutation.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="196">
                    <text>promoter activity in cardiomyocytes is believed to be decreased by their mutation.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="197">
                    <text>promoter activity in cardiomyocytes is decreased by their mutation.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="198">
                    <text>promoter activity in cardiomyocytes is shown to be decreased by their mutation.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="199">
                    <text>promoter activity in cardiomyocytes may be decreased by their mutation.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="200">
                    <text>promoter activity in cardiomyocytes may have been decreased by their mutation.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="201">
                    <text>promoter activity in cardiomyocytes might be decreased by their mutation.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="202">
                    <text>promoter activity in cardiomyocytes was able to be decreased by their mutation.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="203">
                    <text>promoter activity in cardiomyocytes was believed to be decreased by their mutation.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="204">
                    <text>promoter activity in cardiomyocytes was decreased by their mutation.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="205">
                    <text>promoter activity in cardiomyocytes was shown to be decreased by their mutation.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="206">
                    <text>promoter activity in cardiomyocytes will be decreased by their mutation.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="207">
                    <text>promoter activity in cardiomyocytes will have been decreased by their mutation.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="208">
                    <text>promoter activity in cardiomyocytes would be decreased by their mutation.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="209">
                    <text>their mutation can decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="210">
                    <text>their mutation can have decreased promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="211">
                    <text>their mutation causes decreased promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="212">
                    <text>their mutation could decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="213">
                    <text>their mutation decreased promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="214">
                    <text>their mutation decreases promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="215">
                    <text>their mutation has decreased promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="216">
                    <text>their mutation has the ability to decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="217">
                    <text>their mutation is able to decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="218">
                    <text>their mutation is believed to decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="219">
                    <text>their mutation is shown to decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="220">
                    <text>their mutation may decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="221">
                    <text>their mutation may have decreased promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="222">
                    <text>their mutation might decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="223">
                    <text>their mutation was able to decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="224">
                    <text>their mutation was believed to decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="225">
                    <text>their mutation was shown to decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="226">
                    <text>their mutation will decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="227">
                    <text>their mutation will have decreased promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="228">
                    <text>their mutation would decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="REPLACE" no="1">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, levels of Clara cell secretory protein was significantly decreased (4050%; see Table 2).</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="REPLACE" no="2">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, the protection was significantly decreased (4050%; see Table 2).</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="REPLACE" no="3">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels can be lowered and levels of Clara cell secretory protein can be decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="REPLACE" no="4">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels can be lowered and the protection can be decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="REPLACE" no="5">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels can have been lowered and levels of Clara cell secretory protein can have been decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="REPLACE" no="6">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels can have been lowered and the protection can have been decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="REPLACE" no="7">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels is able to be lowered and levels of Clara cell secretory protein is able to be decreased), and neither RAP2 nor RAP3 is be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="REPLACE" no="8">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels is able to be lowered and the protection is able to be decreased), and neither RAP2 nor RAP3 is be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="REPLACE" no="9">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels is lowered and levels of Clara cell secretory protein is decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="REPLACE" no="10">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels is lowered and the protection is decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="REPLACE" no="11">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels may be lowered and levels of Clara cell secretory protein may be decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="REPLACE" no="12">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels may be lowered and the protection may be decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="REPLACE" no="13">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels may have been lowered and levels of Clara cell secretory protein may have been decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="REPLACE" no="14">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels may have been lowered and the protection may have been decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="REPLACE" no="15">
                    <text>In contrast, only low levels of the truncated RAP1 peptides have been detected (consistent with that expression levels has been lowered and levels of Clara cell secretory protein has been decreased), and neither RAP2 nor RAP3 has been co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="REPLACE" no="16">
                    <text>In contrast, only low levels of the truncated RAP1 peptides have been detected (consistent with that expression levels has been lowered and the protection has been decreased), and neither RAP2 nor RAP3 has been co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="REPLACE" no="17">
                    <text>In contrast, only low levels of the truncated RAP1 peptides were detected (consistent with that expression levels could be lowered and levels of Clara cell secretory protein could be decreased), and neither RAP2 nor RAP3 was co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="REPLACE" no="18">
                    <text>In contrast, only low levels of the truncated RAP1 peptides were detected (consistent with that expression levels could be lowered and the protection could be decreased), and neither RAP2 nor RAP3 was co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="REPLACE" no="19">
                    <text>In contrast, only low levels of the truncated RAP1 peptides were detected (consistent with that expression levels might be lowered and levels of Clara cell secretory protein might be decreased), and neither RAP2 nor RAP3 was co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="REPLACE" no="20">
                    <text>In contrast, only low levels of the truncated RAP1 peptides were detected (consistent with that expression levels might be lowered and the protection might be decreased), and neither RAP2 nor RAP3 was co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="REPLACE" no="21">
                    <text>In contrast, only low levels of the truncated RAP1 peptides were detected (consistent with that expression levels was able to be lowered and levels of Clara cell secretory protein was able to be decreased), and neither RAP2 nor RAP3 was be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="REPLACE" no="22">
                    <text>In contrast, only low levels of the truncated RAP1 peptides were detected (consistent with that expression levels was able to be lowered and the protection was able to be decreased), and neither RAP2 nor RAP3 was be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="REPLACE" no="23">
                    <text>In contrast, only low levels of the truncated RAP1 peptides were detected (consistent with that expression levels was lowered and levels of Clara cell secretory protein was decreased), and neither RAP2 nor RAP3 was co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="REPLACE" no="24">
                    <text>In contrast, only low levels of the truncated RAP1 peptides were detected (consistent with that expression levels was lowered and the protection was decreased), and neither RAP2 nor RAP3 was co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="REPLACE" no="25">
                    <text>In contrast, only low levels of the truncated RAP1 peptides will be detected (consistent with that expression levels will be lowered and levels of Clara cell secretory protein will be decreased), and neither RAP2 nor RAP3 will be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="REPLACE" no="26">
                    <text>In contrast, only low levels of the truncated RAP1 peptides will be detected (consistent with that expression levels will be lowered and the protection will be decreased), and neither RAP2 nor RAP3 will be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="REPLACE" no="27">
                    <text>In contrast, only low levels of the truncated RAP1 peptides will be detected (consistent with that expression levels will have been lowered and levels of Clara cell secretory protein will have been decreased), and neither RAP2 nor RAP3 will be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="REPLACE" no="28">
                    <text>In contrast, only low levels of the truncated RAP1 peptides will be detected (consistent with that expression levels will have been lowered and the protection will have been decreased), and neither RAP2 nor RAP3 will be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="REPLACE" no="29">
                    <text>In contrast, only low levels of the truncated RAP1 peptides would be detected (consistent with that expression levels would be lowered and levels of Clara cell secretory protein would be decreased), and neither RAP2 nor RAP3 would be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="REPLACE" no="30">
                    <text>In contrast, only low levels of the truncated RAP1 peptides would be detected (consistent with that expression levels would be lowered and the protection would be decreased), and neither RAP2 nor RAP3 would be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the protection</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
